ĐÁNH GIÁ HIỆU QUẢ VÀ AN TOÀN CỦA INFLIXIMAB TRONG ĐIỀU TRỊ BỆNH NHÂN VIÊM RUỘT MẠN TẠI KHOA TIÊU HÓA BỆNH VIỆN ĐẠI HỌC Y DƯỢC TP HCM

Abstract

Objective: Inflammatory bowel disease (IBD) poses a significant therapeutic challenge. Infliximab, a TNF-α inhibitor, has demonstrated efficacy, but data from Vietnam are scarce. This study evaluated Infliximab's efficacy and safety in IBD patients in Ho Chi Minh City. Subject and Methods: A retrospective and prospective cohort study encompassing 32 Vietnamese IBD patients (23 CD, 9 UC) treated with Infliximab from November 2019 to December 2023 was conducted. Data on clinical response, endoscopic remission, laboratory markers (CRP, calprotectin), and adverse events were collected. Results: At 54 weeks, clinical response rates were 71.4% for CD and 83.3% for UC. Remission rates were 57.1% for CD and 83.3% for UC. CRP normalization was achieved in 56.3% of CD and 75% of UC patients at 54 weeks. Calprotectin normalization rates at 54 weeks were 66.7% for CD and 40% for UC. Endoscopic remission at 54 weeks was observed in 86.7% of CD and 44.4% of UC patients. Improvement on imaging at 54 weeks was noted in 70.6% of CD patients. Adverse events included hospitalization (31.3%), serious infections (21.9%), opportunistic infections (28.1%). One CD patient (3.1%) died. Conclusion: Infliximab demonstrated significant efficacy and manageable adverse events in treating Vietnamese IBD patients. However, the high rate of infections underscores the importance of stringent pre-treatment screening and close monitoring during therapy. Larger-scale studies are needed to validate these findings and inform optimal management strategies in the Vietnamese context.